Literature DB >> 1677929

Activation and activation-driven death of human gamma/delta T cells.

D Kabelitz1, K Pechhold, A Bender, S Wesselborg, D Wesch, K Friese, O Janssen.   

Abstract

We have concentrated on three functional aspects of human gamma/delta+ T cells. (1) Peripheral blood gamma/delta+ T cells proliferate at a high frequency in response to heat-killed mycobacteria (M.tb.). We present evidence that the primary response of human gamma/delta+ T cells is restricted to those cells bearing a V gamma 9/V delta 2 receptor. (2) T cells expressing the alpha/beta TCR can be activated through the CD2 antigen via an "alternative" pathway. Activation requires the combined signaling of 2 mAb directed against two distinct epitopes of CD2. In striking contrast, cloned gamma/delta+ T cells are activated by a single immobilized anti-CD2 mAb directed against the sheep E-binding epitope of CD2. Stimulation of cloned gamma/delta+ T cells by a single anti-CD2 mAb results in IL-2 production, proliferation, and triggering of cytolytic effector function. (3) Cloned gamma/delta+ T cells are susceptible to programmed cell death (apoptosis) when stimulated simultaneously by anti-CD3/TCR mAb plus exogenous IL-2. The very same clones are activated, however, by the same stimuli in the absence of exogenous IL-2 (but in the presence of LCL feeder cells). This provides the basis for a model where extensive gamma/delta+ T cell proliferation is negatively regulated by antigen plus IL-2.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1677929     DOI: 10.1111/j.1600-065x.1991.tb00588.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  19 in total

1.  Functional gamma delta T-lymphocyte defect associated with human immunodeficiency virus infections.

Authors:  M Wallace; A M Scharko; C D Pauza; P Fisch; K Imaoka; S Kawabata; K Fujihashi; H Kiyono; Y Tanaka; B R Bloom; M Malkovsky
Journal:  Mol Med       Date:  1997-01       Impact factor: 6.354

2.  Preferential activation of peripheral blood V gamma 9+ gamma/delta T cells by group A, B and C but not group D or F streptococci.

Authors:  A Bender; D Kabelitz
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

Review 3.  Human gammadelta-T cells in adoptive immunotherapy of malignant and infectious diseases.

Authors:  Richard D Lopez
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

4.  Interaction between gamma delta T cells and B cells regulating IgG production.

Authors:  G Häcker; S Adam; H Wagner
Journal:  Immunology       Date:  1995-01       Impact factor: 7.397

Review 5.  Role of gamma delta T cells in immunity to infectious diseases and the regulation of hematolymphoid cell development.

Authors:  S R Carding
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

6.  Gamma delta lymphocytes in endocrine autoimmunity: evidence of expansion in Graves' disease but not in type 1 diabetes.

Authors:  I C Roura-Mir; L Alcalde; F Vargas; E Tolosa; G Obiols; M Foz; D Jaraquemada; R Pujol-Borrell
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

7.  Predominant activation and expansion of V gamma 9-bearing gamma delta T cells in vivo as well as in vitro in Salmonella infection.

Authors:  T Hara; Y Mizuno; K Takaki; H Takada; H Akeda; T Aoki; M Nagata; K Ueda; G Matsuzaki; Y Yoshikai
Journal:  J Clin Invest       Date:  1992-07       Impact factor: 14.808

8.  Human TcR gamma delta+ lymphocyte response on primary exposure to Plasmodium falciparum.

Authors:  C Roussilhon; M Agrapart; P Guglielmi; A Bensussan; P Brasseur; J J Ballet
Journal:  Clin Exp Immunol       Date:  1994-01       Impact factor: 4.330

Review 9.  Cytotoxic and regulatory properties of circulating Vδ1+ γδ T cells: a new player on the cell therapy field?

Authors:  Gabrielle M Siegers; Lawrence S Lamb
Journal:  Mol Ther       Date:  2014-06-04       Impact factor: 11.454

10.  CD4+ CD25(high) Foxp3+ regulatory T cells downregulate human Vdelta2+ T-lymphocyte function triggered by anti-CD3 or phosphoantigen.

Authors:  C Scott Mahan; Jeremy J Thomas; W Henry Boom; Roxana E Rojas
Journal:  Immunology       Date:  2008-11-14       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.